J
Junya Yoneda
Researcher at Ajinomoto
Publications - 43
Citations - 2367
Junya Yoneda is an academic researcher from Ajinomoto. The author has contributed to research in topics: Matrigel & Metastasis. The author has an hindex of 22, co-authored 43 publications receiving 2323 citations. Previous affiliations of Junya Yoneda include University of Texas MD Anderson Cancer Center & Hokkaido University.
Papers
More filters
Journal ArticleDOI
Expression of Angiogenesis-Related Genes and Progression of Human Ovarian Carcinomas in Nude Mice
Junya Yoneda,Hiroki Kuniyasu,Marta A. Crispens,Janet E. Price,Corazon D. Bucana,Isaiah J. Fidler +5 more
TL;DR: The expression of various genes that regulates angiogenesis in human ovarian carcinomas is associated with the pattern of the disease and its progression, and targeting specific genes that regulateAngiogenesis could offer new approaches to the treatment of ovarian cancer.
Journal ArticleDOI
Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation
Ikuo Saiki,Junya Yoneda,Ichiro Azuma,Hideji Fujii,Fuminori Abe,Motowo Nakajima,Takashi Tsuruo +6 more
TL;DR: The invasion of human metastatic tumor cells into Matrigel‐coated filters was inhibited by an anti‐CD 13 MAb, WM15, in a concentration‐dependent manner, but this MAb did not have any effect on tumor‐cell adhesion and migration to the extracellular matrices, which may be involved in tumor‐ cell invasion.
Journal ArticleDOI
Regulation of distinct steps of angiogenesis by different angiogenic molecules.
TL;DR: Data demonstrate that different angiogenic molecules differentially regulate distinct steps in the process of angiogenesis, suggesting that any given molecule may be necessary but in itself insufficient for establishment of a viable vasculature.
Journal ArticleDOI
Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
TL;DR: The results suggest that blockade of the VEGF/VPF receptor may be an efficient strategy to inhibit formation of malignant ascites and growth of VEGf/VPf-dependent human ovarian carcinomas.